Article Details

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

Retrieved on: 2023-01-13 16:41:58

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia. View article details on hiswai:

Excerpt

In August 2023, AstraZeneca will advise distributors to halt distribution of the agent and request the return of moxetumomab pasudotox packs.

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up